CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:FOXO1 is a master regulator of CAR T memory programming.
FOXO1 is a master regulator of CAR T memory programming.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T 细胞持久性不足限制了其治疗B细胞恶性肿瘤和实体瘤的效果。记忆相关基因(如TCF7,其蛋白为TCF1)的表达与患者应答和长期持久性相关,提示记忆程序对治疗效力至关重要。
本研究显示,先锋转录因子FOXO1可促进人CAR-T 细胞的记忆程序并抑制耗竭。在人CAR-T 细胞中药理抑制或基因编辑内源性FOXO1,会降低记忆相关基因表达,促使细胞呈现耗竭样表型,并损害体内外抗肿瘤活性。过表达FOXO1可诱导符合T细胞记忆特征的基因表达程序,并增加FOXO1结合基序处的染色质可及性。在持续刺激条件下,FOXO1过表达细胞仍能保持功能、记忆潜能和代谢适能,并在体内表现出更强持久性和抗肿瘤活性。相比之下,过表达TCF1既未能建立经典记忆程序,也未增强CAR-T 效力。
重要的是,患者内源性FOXO1活性与CAR-T 及TIL应答相关,凸显其在癌症免疫治疗中的临床意义。研究结果表明,通过FOXO1重编程记忆状态可提高人CAR-T 细胞的持久性和效力,并提示可利用结合凝聚染色质、诱导局部表观遗传重塑的先锋因子来优化治疗性T细胞状态。
Poor CAR T persistence limits CAR T cell therapies for B cell malignancies and solid tumors 1,2 . The expression of memory-associated genes such as TCF7 (protein name TCF1) is linked to response and long-term persistence in patients 3-7 , thereby implicating memory programs in therapeutic efficacy.
Here, we demonstrate that the pioneer transcription factor, FOXO1, is responsible for promoting memory programs and restraining exhaustion in human CAR T cells. Pharmacologic inhibition or gene editing of endogenous FOXO1 in human CAR T cells diminished the expression of memory-associated genes, promoted an exhaustion-like phenotype, and impaired antitumor activity in vitro and in vivo .
FOXO1 overexpression induced a gene expression program consistent with T cell memory and increased chromatin accessibility at FOXO1 binding motifs. FOXO1-overexpressing cells retained function, memory potential, and metabolic fitness during settings of chronic stimulation and exhibited enhanced persistence and antitumor activity in vivo . In contrast, TCF1 overexpression failed to enforce canonical memory programs or enhance CAR T cell potency.
Importantly, endogenous FOXO1 activity correlated with CAR T and TIL responses in patients, underscoring its clinical relevance in cancer immunotherapy.
Our results demonstrate that memory reprogramming through FOXO1 can enhance the persistence and potency of human CAR T cells and highlights the utility of pioneer factors, which bind condensed chromatin and induce local epigenetic remodeling, for optimizing therapeutic T cell states.
MEMBER ACCOUNT
登录成功会直接打开下一页。